Cyclooxygenase 1 Inhibitor Market Growth Opportunities by 2030

Cyclooxygenase 1 inhibitors are a kind of non-steroidal anti-inflammatory drugs. Cyclooxygenase 1 is a type of enzyme that is primarily responsible for pain and inflammation. They are mainly responsible for the production of prostaglandins. The induction of COX2 during inflammation has caused the development of several nonselective therapeutic COX1 and COX2 inhibitors that includes ibuprofen, ketoprofen, flurbiprofen, fenoprofen

In 1991, Simmons and his colleagues recognized a second cyclooxygenase enzyme that is designated cyclooxygenase-2 and derived from a separate gene from cyclooxygenase-1. Increasing research regarding the use of cox 1 inhibitors and advanced technological features are primarily responsible for the growth of cyclooxygenase 1 inhibitor market globally. Furthermore, growing occurrence of cancer cases and neuro-inflammatory diseases can also increase the growth of this market.

Data Bridge Market Research analyses a growth rate in the cyclooxygenase 1 inhibitor market in the forecast period 2023-2030. The expected CAGR of cyclooxygenase 1 inhibitor market is tend to be around 7% in the mentioned forecast period. The market is valued at USD 70 billion in 2022, and it would grow upto USD 120.27 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

North America has been witnessing a positive growth for cyclooxygenase 1 inhibitor market throughout the forecasted period because of the increasing focus of major market players on novel technology.

Read Full Report Summary @ https://www.databridgemarketresearch.com/reports/global-cyclooxygenase-1-inhibitor-market

Asia-Pacific dominates the market because of the high occurrence of cancer cases and inflammatory diseases. Furthermore, Europe is considered to have huge growth prospects in the upcoming years.

Key players operating in the cyclooxygenase 1 inhibitor market include:

Related Reports:

About Data Bridge Market Research, Private Ltd

Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

Article source: https://article-realm.com/article/Sports-Recreation/43017-Cyclooxygenase-1-Inhibitor-Market-Growth-Opportunities-by-2030.html